Skip to main content

Table 2 Comparative analysis of clinical baseline data between the c-Met low expression and high expression groups

From: Study on the expression of c-Met in gastric cancer and its correlation with preoperative serum tumor markers and prognosis

Variable c-Met expression [n (%)/mean (SD)] t/X2 p-value
c-Met low group (n = 34) c-Met high group (n = 63)
Age (years) 57.35 (10.63) 59.95 (9.61) 1.224 0.224
Sex
 Female 11 (32.35) 12 (19.05) 2.161 0.142
 Male 23 (67.65) 51 (80.95)
Tumor diameter (cm) 3.74 (1.82) 4.11 (1.75) 1.001 0.319
Tumor location
 Gastric body 5 (14.71) 9 (14.29) 0.554 0.758
 Gastric antrum 25 (73.53) 43 (68.25)
 Gastric fundus 4 (11.76) 11 (17.46)
T stage
 T (1, 2) 13 (38.24) 13 (20.63) 3.487 0.062
 T (3, 4) 21 (61.76) 50 (79.37)
N stage
 N− 11 (32.35) 16 (25.40) 0.532 0.466
 N+ 23 (67.65) 47 (74.60)
M stage
 M− 33 (97.06) 51 (80.95) 4.936 0.022
 M+ 1 (2.94) 12 (19.05)
Clinicopathologic stage
 I–II 22 (64.71) 25 (39.68) 5.536 0.019
 III–IV 12 (35.29) 38 (60.32)
Differentiated degree
 Poor differentiation 14 (41.18) 40 (63.49) 4.908 0.086
 Moderate differentiation 17 (50.00) 21 (33.33)
 High differentiation 3 (8.82) 2 (3.17)
HER2-IHC
 Missing 1 (2.94) 1 (1.59)   
 Negative 31 (91.18) 56 (88.89) 0.365 0.546
 Positive 2 (5.88) 6 (9.52)
H. pylori
 Missing 6 (17.65) 17 (26.98)   
 Negative 14 (41.18) 23 (36.51) 0.001 1.000
 Positive 14 (41.18) 23 (36.51)